Abstracts tagged "Comorbidity and spondylarthritis"

Abstract Number: 2748 • 2016 ACR/ARHP Annual Meeting
Prevalence of Comorbidities in Patients with Axial Spondyloarthritis and Its Association with Aspects of the Disease
Maria Celeste Orozco¹, Ana Lizarraga², Graciela Betancur², Natalia Zamora¹, Fernando Andres Sommerfleck³, Emilce Schneeberger⁴ and Gustavo Citera⁴, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: The presence of comorbidities in patients with rheumatic diseases affects functional capacity and quality of life, but also they can limit the therapeutic approach…
Abstract Number: 1058 • 2015 ACR/ARHP Annual Meeting
Prevalence of Comorbidities in Spondyloarthritis and Evaluation of Their Monitoring: Results of the International Cross-Sectional ASAS-Comospa Study
Anna Moltó¹, Adrien Etcheto¹, Désirée van der Heijde², Robert B. M. Landewé³, Filip van Den Bosch⁴, Maxime Dougados⁵ and on behalf of the ASAS-COMOSPA task force, ¹Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité,, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Univ Hosp, Ghent, Belgium, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Increased risk of cardio-vascular disease, and osteoporosis is documented in SpA. Some of these comorbidities (e.g. cardiovascular disease risk) are subject to recommendations, with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].